S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
NASDAQ:SCYX

SCYNEXIS - SCYX Stock Forecast, Price & News

$1.74
+0.03 (+1.75%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.71
$1.79
50-Day Range
$1.44
$2.45
52-Week Range
$1.42
$5.27
Volume
88,908 shs
Average Volume
86,937 shs
Market Capitalization
$56.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.67

SCYNEXIS MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
340.6% Upside
$7.67 Price Target
Short Interest
Healthy
2.69% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.87) to ($1.06) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

436th out of 1,030 stocks

Pharmaceutical Preparations Industry

216th out of 502 stocks

SCYX stock logo

About SCYNEXIS (NASDAQ:SCYX) Stock

SCYNEXIS, Inc. is a biotechnology company engaged in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Receive SCYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter.

SCYX Stock News Headlines

Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
SCYNEXIS Third Quarter 2022 Earnings: Misses Expectations
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Scynexis: No Compelling Reason To Invest
See More Headlines
Receive SCYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter.

SCYX Company Calendar

Last Earnings
11/09/2022
Today
2/02/2023
Next Earnings (Estimated)
4/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SCYX
Employees
38
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.67
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+340.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-32,870,000.00
Net Margins
-1,864.15%
Pretax Margin
-1,977.02%

Debt

Sales & Book Value

Annual Sales
$13.16 million
Book Value
$1.72 per share

Miscellaneous

Free Float
31,233,000
Market Cap
$56.83 million
Optionable
Optionable
Beta
2.01

Key Executives

  • David Angulo Gonzalez
    President, Chief Executive Officer & Director
  • Ivor MacLeod
    Chief Financial & Accounting Officer
  • Nkechi Azie
    VP-Clinical Development & Medical Affairs
  • Jim Maffezzoli
    Vice President-Marketing & Sales
  • Scott Sukenick
    Secretary & General Counsel













SCYX Stock - Frequently Asked Questions

Should I buy or sell SCYNEXIS stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SCYX shares.
View SCYX analyst ratings
or view top-rated stocks.

What is SCYNEXIS's stock price forecast for 2023?

2 Wall Street research analysts have issued twelve-month price objectives for SCYNEXIS's shares. Their SCYX share price forecasts range from $7.00 to $8.00. On average, they anticipate the company's stock price to reach $7.67 in the next year. This suggests a possible upside of 340.6% from the stock's current price.
View analysts price targets for SCYX
or view top-rated stocks among Wall Street analysts.

How have SCYX shares performed in 2023?

SCYNEXIS's stock was trading at $1.56 at the start of the year. Since then, SCYX shares have increased by 11.5% and is now trading at $1.74.
View the best growth stocks for 2023 here
.

When is SCYNEXIS's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our SCYX earnings forecast
.

How were SCYNEXIS's earnings last quarter?

SCYNEXIS, Inc. (NASDAQ:SCYX) released its earnings results on Wednesday, November, 9th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $0.11. The firm earned $1.56 million during the quarter, compared to analyst estimates of $1.89 million. SCYNEXIS had a negative net margin of 1,864.15% and a negative trailing twelve-month return on equity of 275.25%.

When did SCYNEXIS's stock split?

SCYNEXIS shares reverse split on the morning of Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of SCYNEXIS own?
What is SCYNEXIS's stock symbol?

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

Who are SCYNEXIS's major shareholders?

SCYNEXIS's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wealth Effects LLC (0.19%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brian Philippe Tinmouth, Eric Francois, Marco Taglietti, Perceptive Advisors Llc and Scott Sukenick.
View institutional ownership trends
.

How do I buy shares of SCYNEXIS?

Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SCYNEXIS's stock price today?

One share of SCYX stock can currently be purchased for approximately $1.74.

How much money does SCYNEXIS make?

SCYNEXIS (NASDAQ:SCYX) has a market capitalization of $56.83 million and generates $13.16 million in revenue each year. The company earns $-32,870,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis.

How can I contact SCYNEXIS?

SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The official website for the company is www.scynexis.com. The company can be reached via phone at (201) 884-5485, via email at ikoffler@lifesciadvisors.com, or via fax at 201-884-5490.

This page (NASDAQ:SCYX) was last updated on 2/3/2023 by MarketBeat.com Staff